EFFECTS OF A TYPICAL ANTIPSYCHOTIC AND THROMBOXANE A2 SYNTHASE INHIBITOR DRUG COMBINATION ON ALBUMIN AND TOTAL PROTEIN LEVEL WITH DIFFERENT DOSES IN RATS

Effects of Atypical Antipsychotic and Thromboxane A2 Synthase inhibitor drug Combination on Albumin and Total Protein Level

  • MUHAMMAD IRFAN BASHIR Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore, Pakistan.

Abstract

Objective: The objective of this study was to investigate the combined as well as individual effects of a typical antipsychotic and thromboxane A2 synthase inhibitor on albumin and total protein level with minimum and maximum dose comparison in rats.


Methods: This study consisted of 100 albino rats of 300 to 340 g from both gender, there were 10 groups, each contained 10 rats (n=10). Rats were treated with defined dose of zuclopenthixol (Zuclo) and ozagrel (Ozg) for 21 days (3 weeks). Blood samples were collected at 0, 7th, 14th, and 21st days of study. Albumin and total protein level were examined from blood samples using standard laboratory procedure. Results are extracted by applying statistical analysis on data and comparing percentage variation from 0-day value.


Results: A typical antipsychotic-treated group showed gradually significant increase in albumin and total protein level, TXA2 synthase inhibitor-treated group also showed significant gradually increase in albumin and total protein level in combination groups, they showed highly significant increase p<0.001 in both parameter with maximum dose.


Conclusion: Combination treatment with zuclopenthixol (Zuclo) and ozagrel (Ozg) can cause large increase on albumin and total protein level with maximum dose as compare to individual drug treatment.

Keywords: Atypical antipsychotic,, Thromboxane A2 synthase,, Zuclopenthixol,, Albumin,, Total protein level,, Ozagrel.

References

1. Capaldi VF 2nd, Wynn GH. Emerging strategies in the treatment of poststroke depression and psychiatric distress in patients. Psychol Res Behav Manag 2010;3:109-18.
2. Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer’s disease. Cochrane Database of Syst Rev 2006;1:CD003476.
3. Seeman P. Atypical antipsychotics: Mechanism of action. Focus 2004;47:27-58.
4. Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, et al. A review of liver function tests during treatment with atypical antipsychotic drugs: A chart review study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1255-60.
5. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Euro Neuropsychopharmacol 2001;11:25-32.
6. Pahari N, Tripathi SK, Maity T, Gupta BK, Bagchi C, Mondal DK. Evaluation and analysis of adverse drug reactions of second generation antipsychotics in a psychiatry out-patient department. Int J Pharm Pharm Sci 2012;4:158-62.
7. Takabatake Y, Uno E, Wakamatsu K, Yamazaki N, Hashimoto N, Tsuchiya Y, et al. The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction. No To Shinkei 2003;55:589-93.
8. Tomishima Y, Ishitsuka Y, Matsunaga N, Nagatome M, Furusho H, Irikura M, et al. Ozagrel hydrochloride, a selective thromboxane A2 synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice. BMC Gastroenterol 2013;13:21.
9. Mesitskaya DF, Syrkin AL, Aksenova MG, Zhang Y, Zamyatnin J, Andrey A, et al. Thromboxane a synthase: A new target for the treatment of cardiovascular diseases. Cardiovasc Hematol Agents Med Chem 2018;16:81-7.
10. Cabrerizo S, Cuadras D, Gomez-Busto F, Artaza-Artabe I, Marín-Ciancas F, Malafarina V, et al. Serum albumin and health in older people: Review and meta analysis. Maturitas 2015;81:17-27.
11. Vincent JL. Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesthesiol 2009;23:183-91.
12. Yap CY, Aw TC. Liver function tests (LFts). Proc Singapore Healthc 2010;19:80-2.
13. Somaji L, Rapolu R. Binding studies of valganciclovir to human serum albumin by multispectroscopic techniques. Int J Pharm Pharm Sci 2018;10:87-92.
14. Mohamed NY. Evaluation of Plasma Levels of Total Protein and Albumin in Sudanese Children with Malnutrition in Khartoum State. Khartoum: Sudan University of Science and Technology; 2017.
15. Orhue N, Nwanze E, Akafor A. Serum total protein, albumin and globulin levels in Trypanosoma brucei infected rabbits: Effect of orally administered Scoparia dulcis. Afr J Biotechnol 2005;4:1152-5.
16. Bashir MI, Saleem U, Anwer F, Ahmad B. Effects of thioxanthene containing anti-psychotic and anti-platelet drug combination on mean platelet volume and platelet distribution width in rats. J Pharm Res Int 2019;27:1-7.
17. Hira S, Saleem U, Anwar F, Ahmad B. Antioxidants attenuate isolation-and L-DOPA-induced aggression in mice. Front Pharmacol 2017;8:945.
18. Khedr EM, Al Fawal B, Abdelwarith AM, Saber M, Tony AAH, El-Bassiony A, et al. Changes in recruitment of motor cortex excitation and inhibition in patients with drug-induced tardive syndromes. Neurophysiol Clin 2019;49:33-40.
19. Tsukamoto A, Uchida K, Maesato S, Sato R, Kanai E, Inomata T, et al. Combining isoflurane anesthesia with midazolam and butorphanol in rats. Exp Anim 2016;65:223-30.
20. Marwick KF, Taylor M, Walker SW. Antipsychotics and abnormal liver function tests: Systematic review. Clin Neuropharmacol 2012;35:244-53.
21. Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6. Drug Metab Dispos 1999;27:1078-84.
22. Mahmoud MR, El-Abhar HS, Saleh S. The effect of Nigella sativa oil against the liver damage induced by Schistosoma mansoni infection in mice. J Ethnopharmacol 2002;79:1-11.
23. Blaschke TF. Protein binding and kinetics of drugs in liver diseases. Clin Pharmacokinet 1977;2:32-44.
Statistics
203 Views | 61 Downloads
Citatons
How to Cite
MUHAMMAD IRFAN BASHIR. “EFFECTS OF A TYPICAL ANTIPSYCHOTIC AND THROMBOXANE A2 SYNTHASE INHIBITOR DRUG COMBINATION ON ALBUMIN AND TOTAL PROTEIN LEVEL WITH DIFFERENT DOSES IN RATS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 12, no. 7, June 2019, pp. 316-9, doi:10.22159/ajpcr.2019.v12i7.34122.
Section
Original Article(s)